Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VIRX

Viracta Therapeutics (VIRX) Stock Price, News & Analysis

Viracta Therapeutics logo

About Viracta Therapeutics Stock (NASDAQ:VIRX)

Advanced Chart

Key Stats

Today's Range
$0.0098
$0.0098
50-Day Range
$0.0096
$0.0178
52-Week Range
$0.01
$0.56
Volume
N/A
Average Volume
1.11 million shs
Market Capitalization
$388.70 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.13
Consensus Rating
Moderate Buy

Company Overview

Viracta Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

VIRX MarketRank™: 

Viracta Therapeutics scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Viracta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Viracta Therapeutics has received no research coverage in the past 90 days.

  • Read more about Viracta Therapeutics' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Viracta Therapeutics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Viracta Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Viracta Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.04% of the outstanding shares of Viracta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Viracta Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viracta Therapeutics has recently increased by 76.54%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Viracta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Viracta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.04% of the outstanding shares of Viracta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Viracta Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Viracta Therapeutics has recently increased by 76.54%, indicating that investor sentiment is decreasing significantly.
  • MarketBeat Follows

    1 people have added Viracta Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Viracta Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.69% of the stock of Viracta Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.37% of the stock of Viracta Therapeutics is held by institutions.

  • Read more about Viracta Therapeutics' insider trading history.
Receive VIRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viracta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VIRX Stock News Headlines

INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.tc pixel
Viracta Therapeutics terminates employees, to wind down operations
Viracta Therapeutics Announces Wind Down of Operations
See More Headlines

VIRX Stock Analysis - Frequently Asked Questions

Viracta Therapeutics, Inc. (NASDAQ:VIRX) issued its earnings results on Wednesday, November, 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.09.

Based on aggregate information from My MarketBeat watchlists, some other companies that Viracta Therapeutics investors own include Meta Platforms (META), Intel (INTC), Applied Genetic Technologies (AGTC), C3.ai (AI), Advanced Micro Devices (AMD) and NVIDIA (NVDA).

Company Calendar

Last Earnings
11/10/2021
Today
8/28/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VIRX
CIK
1061027
Employees
20
Year Founded
N/A

Price Target and Rating

High Price Target
$2.00
Low Price Target
$0.25
Potential Upside/Downside
+11,403.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$51.06 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-1,899.61%
Return on Assets
-114.21%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.76
Quick Ratio
0.76

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.33 per share
Price / Book
0.03

Miscellaneous

Outstanding Shares
39,744,000
Free Float
35,495,000
Market Cap
$388.70 thousand
Optionable
No Data
Beta
1.06
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:VIRX) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners